Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tonight all the networks are showing a Cancer special
wouldn't it be nice if they mentioned PPHM
Who remembers Joe E Lewis when he used to say
IS EVERYBODY HAPPY.
Just a guess, but I think there is more to this halt then news from Chicago.
Jonthpilot was posting about a melonoma
Strip House is good for me. I'm still under water
I need 4.07 to break even but I can still afford dinner in NYC.When I retired in 2001 my office was at 76 Ninth Ave up 1 block from the Old Homestead
another great steak house.
John
Mine was scary because they have no idea where it came from. I was lucky that I cought it so soon.
When they removed it they took out all the lympf nodes in the area,I didn't need any radiation or chemo treatment. Good luck to you.
Jay
John
I had a Melanoma removed 2 years ago from behind my ear. Surgery was performed by a Dr J. Goydos at the Cancer Inst Of New Jersey.I have to go back every 3 months for a exam, so far no bad news. I didn'n need any further treatment. On my last vit=sit Dr Goydos was telling me that they are testing a new drug there called Ipaliba(sec)and they are looking at pill.For you golfers out there Dr Goydos is Paul Goydos's brother
I feel sorry for you Loof. While your playing with your Rocket, Tesse May is playing with the Col's
Johnson.
I see a big change in trades today no more 100 share lots but nice trades. I have to feel that things are warming up.
Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ
TUSTIN, CA -- (Marketwire) -- 03/28/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, announced that it received today a notice from The NASDAQ Stock Market indicating that the company's minimum bid price has fallen below $1.00 for 30 consecutive business days, and therefore, was not in compliance with NASDAQ Marketplace Rule 5550(a)(2). The company has been provided 180 calendar days, or until September 24, 2012, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days. This notice does not impact the company's listing on The NASDAQ Stock Market at this time.
If the company does not regain compliance within the initial 180-day period, but otherwise meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, except for the bid price requirement, the company will be granted an additional 180 calendar days to regain compliance. If the company is not eligible for an additional compliance period, NASDAQ will notify the company that its securities will be subject to delisting. At that time, the company may appeal this determination to delist its securities to a Listing Qualification Panel.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and infectious diseases. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com
Source: Peregrine Pharmaceuticals
You are subscribed to Peregrine Pharmaceuticals, Inc. Investor Relations' e-mail alerts as slicklen11@aol.com.
To update your e-mail and alert preferences, please click here.
To unsubscribe, please click here.
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue , Tustin, CA 92780-7017
Service provided by Shareholder.com
These guys sound like they are under water. Sound is garbled.
The obvious has taken place. Co. had agreed to sell
X amount of shares to a party at an agreed price per share. This deal took place about two months ago. the party has sold short for this period and tommorow
the deal will be anounced and the party will take the discounted shares and cover their short. No new big holder of shares just a finiancial profit for the
party that made the deal. We all suffer and the Co. has money to continue their unethical ways and receive their big saleries and bonuses.
Would someone post the date of the reverse split.
I need it for tax purpose.TIA
Jay
Large volumn and a declining price points to one thing. Management has arranged a new discounted sale
which will be announced shortly. I figure 10million at .85.
Questions are all from the same group no private investors
Just suppose the fourth quater ends and no FDA meeting. What will be the excuse from Management?
I for one will be very upset and will no longer trust one thing they say.
Who shot that rally in the foot?
I stand corrected
They can't say anything at the CC if they haven't said it before the meeting. One other thing the PPS has never gone up on the day of a CC
suckers are buying smart money is selling
Watch out, this is phony trading going on right now.
Traders are letting it run and then boom bottom drops out
I say if Peregrine finds a person meeting all the requirements that they are looking for they should fire King and put the new hire in charge.
I need a little info. A friend of mine has had his Prostate removed and now has been diagnosed with cancer in the Lymph nodes
where his Prostate used to be. He wants to go to Duke Univ for treatment. Does anyone know who at Duke would be familiar with Bavi and would it be helpful with treating my friend.
TIA
Jay
Last november I was opperated on for removal of a Melanoma. On a check up last month I mentioned Bavi and Cotara to my surgeon.
He has heard of both and told me to stay with them and not sell
my shares, he mentioned that the Hospital was doing trials on another drug. He mentioned ipilimumab, I wish they would try Bavi.
P.S. My surgery was a success and I didn't need Chemo or Radiation.
Jay
ownsme
Thanks for the info
Who is Shelly Fussey? He sold 5000 shares on 12/31/10 still has 127k
NOTBOB
Happy New Year to you
I don't know if he is or not. I wish he'd take the whole offering.
If he would buy another 2million shares he coud stay close to his 7.5% again I'm talking ball park.I like the way the price is holding and not tanking, in view of the fact we have a dilution of 30 plus million shares.Ball park. I know it depends on the price per share and if it all is going to sell now or a year from now. It will sell it's just a matter of when and what price.
Happy New Year.
Jay
pphm fan and honestabe
You 2 remind me of the kids in my class in school, you raise your hands to answer the questions and you raise your hands to ask question. Funny thing is you are both dumb. I am saying ball park, I know they are selling stock at diferent prices I remind you both I am saying ball park what don't you understand.
It all boils down to my original question. is he going to buy more shares to get back to 7.5 holding.
Fan
I am just taking a ball park number. 75m @2.25 a share 33m shares
add that to the 60m shares outstanding then do the math. Dart has to be under 4%.
With PPHM selling 75 million $ worth of stock this will reduce Darts 7.5% down to under 4% I wonder if he is going to grab some more?
Should we get ready for 20,000 puts at .50?
75 million shares or dollars looks like management is insuring their exaggerated saleries for the future. If I didn't know better I would think Pelosi and Reid were running this company.
I am afraid the fox is in the hen house and he isn't leaving.
Just when it looks like we are moving up they pull us back down.
It would be interesting to know what Mr. Dart thinks about this.
Market closed at 1:00
News Eastern Capital has a 7.1% passive stake in PPHM
If I was a Board Member I would be embarrased to show up today for the SHM.
Nortj
Thanks for the responce. I will study up on these drugs.
I need some help. I have been diagnosed with a Melanoma.
I need to know if Peregrine has a drug to combat Melanoma.
For the past three months I have been seeking advice from my family Doctor who prescribed a Cat Scan a ENT who did a biopsy and a Pet scan then an Oncologist who ordereg a MRI and then sent me to the Cancer Inst, in New Jersey. The Doctors there have me schduled for an Operation on Oct. 28. Do I have the operation or try for a treatment of Cotara or Bavi.
Any advice would be helpful. I have been a stock holder in PPHM for over 12 years I think it's about time PPHM paid me back
TIA Jay
The MM'S making a market and trading PPHM must be getting writers cramp writing all the 100 share trades.It is a joke.
See the difference! Customize Seeking Alpha: Sign in or join Seeking Alpha
Home The Macro View Stocks & Sectors Global Markets ETFs Investing Ideas News, Data, Transcripts Sign in or Join now
Home » Biotech Stocks » Long Ideas, Small Cap
<script type="text/javascript">GA_googleFillSlot_sa("Search_195x45_Dropdown");</script>
Loading...
Symbols:
Authors:
Peregrine Pharmaceuticals: Good Long Term Potential
by: VFC's Stock House June 16, 2010 | about: PPHM Font Size: PrintEmail Recommend 0 Share this page
Share0 VFC's Stock House 1275
Followers 4
Following FollowYou are currently following VFC's Stock House
Stop FollowingYou are no longer following VFC's Stock House
Profile
Articles (206)
StockTalks (1)
Comments (76)
Send Message About this author:
Visit: VFC's Stock House
Submit
an article to It's been a while since I've mentioned Peregrine Pharmaceuticals (PPHM), but I thought that the highs of April and May were a better time to sell than accumulate, so I left it alone. The mini-run earlier this year was based on a flurry of Press Releases outlining encouraging results from the ongoing Phase II trials that were to be presented at ASCO.
Now that the hype has died down a bit and the stock is back to trading for around three dollars, Peregrine Pharmaceuticals may be worth a look as a "Phase II accumulation" pick, with eyes towards the conclusion of the ongoing trials and the future potential of both Bavituximab and Cotara.
Bavituximab is an anti-tumor antibody that alerts one's immune system to attack the cancerous cells and is being investigated for effectiveness in multiple Phase II trials, including advanced breast cancer and other solid tumor indications. Peregrine is also testing this product for use in fighting infectious diseases, and Phase I trials for Hepatitis C and HIV are ongoing.
Cotara is classed as Tumor Necrosis Therapy [TNT] and carries anti-cancer agents into the core of the tumor, attacking them from the inside out. A Phase II trial testing this product in brain cancer patients is ongoing.
There's a lot of potential with these products, although it's worth keeping in mind that Phase II is a long way from market ,so it's worth it to keep a handful of trading shares in store to take advantage of any sudden spikes, like the one we saw during the April / May time frame.
That said, if either or both of these products make it through Phase III trials, then the share price will most likely be trading for much higher prices, so this stock is worth a look as a good mid to long term cancer pick for the current prices, in my opinion.
There's likely to be some additional volatility associated with this one being that significant news could still be months away, but it's likely that the company could offer up trial results late this year.
I like the potential of PPHM.
Disclosure: Long PPHM.
About the author: VFC's Stock House I'm VFC. After years of blowing through spare money and then starting a family, I decided it was time to bear down with the finances and look towards the future; after all, it wasn't just me I had to support anymore. I never trusted the stock market, but I also never trusted handing my hard... More Company: VFC's Stock House Blog: VFC's Stock House1275
Followers4
FollowingFollowSend Message Share this page
0
Share 0 Related Articles
• Gaining Exposure to Gold Through ETFs • Does the Bounce in the Euro Signal All Is Well? • Biflation or Stagflation? It Could Be Both Related stocks: PPHM
Related themes: Long Ideas, Small Cap, Biotech Diagnosis, Biotech Equipment, Biotech Research
Add Your Comment
GuestComment: Publish Submitting comment, please wait ...
PPHM vs. ETF AlternativesSymbol Today 3 Mths 1 Yr YTD
PPHM 1.0% -6.6% -36.3% 4.4%
ETF Alternatives
sponsored by 490,801 people have joined Seeking Alpha to track analysis of stocks they follow & exchange investment ideas
Join now (it's free):Choose Username
you can use your real nameEmail Address:Create Password:I agree to Terms of Use & Privacy Policy
Already joined? Sign inMost PopularWall Street Breakfast: Must-Know News
When to Buy BP
Cramer's Stop Trading! 2 Neglected Plays on Apple (6/14/10)
5 Reliable Dividend Stocks in the News
AT&T Melts Down Again, Will Apple Ever Learn?
3 Reasons This Rally Is Toast
Where Is BP Headed: $70 or $0?
Cramer's Lightning Round - Corning's Disappointments Are Over (6/14/10)
Cramer's Mad Money - Going GaGa Over the Bad Romance With Tech (6/14/10)
Just One Stock: A Thrift Where Being Conservative Pays Dividends
More »Editors' PicksCBOE: A Blue Chip IPO Without a Doubt
Schwab’s Low Fees Are Not About ETFs
Tough Times for Video Game Industry
Nokia: Valuation Appears Tempting but Concerns Remain
Understanding Employment Statistics
More »
The Seeking Alpha 100
The top 100 stock
market authors
selected for publication in the last week1
The Pragmatic... 2
David White 3
Philip Davis 4
John Lounsbury 5
Edward Harrison See all
Seeking Alpha 100 »
Fastest Climbers
Those with the largest
increase in followers
in the last week1
Wall St. Chea... 2
Jim Van Meerten 3
Dr. Kris 4
Gary Tanashian 5
MagicDiligence See all
Fastest Climbers »
Top Commenters
Top commenters,
as ranked by their peers1 User 353732 2 Moon Kil Woong 3 optionsgirl 4 Mayascribe 5 tripleblack See all
Top Commenters »
Top Instabloggers
The 100 most active
Instabloggers.1
Philip Davis 2
John Lounsbury 3
Cliff Wachtel 4
David Fry 5
Dr. Kris See all
Top Instabloggers »
Top StockTalkers
Top
StockTalkers.1
David White 2
Philip Davis 3
Andrew Wilkinson 4
Alan Brochstein 5
Cliff Wachtel See all
Top StockTalkers »
Free E-Newsletters
Wall Street Breakfast - Sample
The Macro View - Sample
Investing Ideas - Sample
Jim Cramer's Picks - Sample
Stocks & Sectors - Sample
Global Markets - Sample
Alt. Energy Investing - Sample
ETF Daily - Sample
The Daily Dispatch - Sample
We don't spam
Tools
Feeds About Seeking Alpha
About Seeking Alpha
Editorial principles
SA transcripts
The SA management
What's New
Who reads SA
SA Team Instablogs
David (Founder)
Eli (Editor in Chief)
Boaz (Contributor Relations) Contact
Contact us
Dispute an article
Advertise
SA Stats
Article stats
Instablog stats
StockTalk stats
Comment stats
Contributor stats For Contributors
Become a contributor
Contributor benefits
Seeking Alpha Certified
Feature your business / blog / book
Policy on anonymous contributors
For Journalists
SA for journalists
Interview a contributor
History and founder quote data from Xignite| Terms of use| Privacy| Copyright
Spell Checker X
Not Found
Replace With
Suggestions
Options
Delete
Replace
Ignore
Learn
Replace All
Ignore All
Spell Check Canceled!
Undo Corrections?
Yes No
Ignore All
Delete RepeatedIgnore